Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (111-120 of 324) with videos related to

Pageof 33
Sort By:
Sexual Health|April 22, 2016
Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort studyNicole L De La Mata, David A Cooper, Darren Russell, et al.
The Open Virology Journal|March 17, 2012
Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in BangkokAmanda Clarke, Stephen Kerr, Adam Honeybrook, et al.
Plos One|March 8, 2012
Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNAYu Ming Paul Lam, Kristin L McBride, Janaki Amin, et al.
Plos One|September 9, 2017
Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLES)Kathy Petoumenos, Robin Huang, Jennifer Hoy, et al.
Journal of the International AIDS Society|April 14, 2015
Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in AustraliaStephen T Wright, Matthew G Law, David A Cooper, et al.
Expert Opinion on Investigational Drugs|September 13, 2002
Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countriesGilbert R Kaufmann, Don Smith, Heiner C Bucher, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2005
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapyAlan Winston, Mark Bloch, Andrew Carr, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?John T Lucas, David A Cooper, Scott Hwang, et al.
HIV Clinical Trials|February 11, 2003
Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophyDon E Smith, Jeff Hudson, Allison Martin, et al.
Nucleic Acid Therapeutics|September 24, 2025
Cryopreservation of siRNA-Treated Cells Is FeasibleMelanie Sauer, Xavier Segarra-Visent, Leon Breuer, et al.
Pageof 33

Showing results (111-120 of 324) with videos related to

Sort By:
Pageof 33
Sexual Health|April 22, 2016
Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort studyNicole L De La Mata, David A Cooper, Darren Russell, et al.
The Open Virology Journal|March 17, 2012
Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in BangkokAmanda Clarke, Stephen Kerr, Adam Honeybrook, et al.
Plos One|March 8, 2012
Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNAYu Ming Paul Lam, Kristin L McBride, Janaki Amin, et al.
Plos One|September 9, 2017
Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLES)Kathy Petoumenos, Robin Huang, Jennifer Hoy, et al.
Journal of the International AIDS Society|April 14, 2015
Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in AustraliaStephen T Wright, Matthew G Law, David A Cooper, et al.
Expert Opinion on Investigational Drugs|September 13, 2002
Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countriesGilbert R Kaufmann, Don Smith, Heiner C Bucher, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2005
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapyAlan Winston, Mark Bloch, Andrew Carr, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?John T Lucas, David A Cooper, Scott Hwang, et al.
HIV Clinical Trials|February 11, 2003
Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophyDon E Smith, Jeff Hudson, Allison Martin, et al.
Nucleic Acid Therapeutics|September 24, 2025
Cryopreservation of siRNA-Treated Cells Is FeasibleMelanie Sauer, Xavier Segarra-Visent, Leon Breuer, et al.
Pageof 33